Provention Bio files for FDA approval on resurrected diabetes drug

If approved, teplizumab will be the first disease-modifying therapy for type 1 diabetes
Jan. 4, 2021
2 min read

Provention Bio has filed an FDA marketing application for teplizumab, a humanized anti-CD3 monoclonal antibody, for the delay or prevention of clinical type 1 diabetes in at-risk individuals.

The FDA has granted a priority review for the diabetes drug with action date set at July 2, 2021. The company says if approved, teplizumab will be the first disease-modifying therapy for type 1 diabetes.

The drug has a long history. Back in 2007, Eli Lilly and MacroGenics partnered to develop and commercialize teplizumab, well as other potential next generation anti-CD3 molecules for use in the treatment of autoimmune diseases. Then, in 2010, teplizumab failed a pivotal late-stage diabetes study undertaken by Eli Lilly and the drugmaker handed the rights back to MacroGenics. In 2018, the NJ-based startup — Provention Bio — in-licensed the drug from MacroGenics and used it as their lead drug for a $56 million IPO filing.

Since then,  teplizumab has shown value in preserving beta cells in the pancreas, reducing the need for insulin among Type 1 patients. New trial data announced last June show the drug delayed progression to clinical type 1 diabetes in high-risk participants, increased the average amount of time it takes for a patient to be diagnosed with type 1 diabetes to five years.

The FDA said it’s planning to hold an advisory committee meeting on May 27, 2021.

Read the press release

Sign up for Pharma Manufacturing Newsletters
Get the latest news and updates